Shanghai Pulmonary Hospital, Shanghai, China

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC

Phase 3, Recruiting, 2026, 290 people, 7 Oct 2026, clinicaltrials.gov

NCT07754812

Phase 4, Recruiting, 2026, 78 people, 10 Aug 2026, clinicaltrials.gov

NCT07493980

Phase 2, Not yet recruiting, 2026, 54 people, 27 Mar 2026, clinicaltrials.gov

NCT07097948

Phase 2, Not yet recruiting, 2025, 40 people, 1 Aug 2025, clinicaltrials.gov

NCT06837948

Phase 2, Not yet recruiting, 2025, 160 people, 20 Feb 2025, clinicaltrials.gov

NCT06749886

Phase 2, Recruiting, 2024, 22 people, 27 Dec 2024, clinicaltrials.gov

NCT06648200

Phase 2, Not yet recruiting, 2024, 100 people, 18 Oct 2024, clinicaltrials.gov

NCT06620796

Phase 2, Not yet recruiting, 2024, 70 people, 1 Oct 2024, clinicaltrials.gov

NCT06463171

Phase 2, Status unknown, 2024, 60 people, 17 Jun 2024, clinicaltrials.gov

NCT06256237

Phase 2, Recruiting, 2024, 30 people, 13 Feb 2024, clinicaltrials.gov

NCT05894889

Collaborator, Phase 2, Active, not recruiting, 2024, 70 people, 8 Jun 2023, clinicaltrials.gov

NCT05891080

Phase 2, Not yet recruiting, 2023, 124 people, 6 Jun 2023, clinicaltrials.gov

NCT05766800

Phase 2, Recruiting, 2023, 100 people, 13 Mar 2023, clinicaltrials.gov

NCT05493267

Phase 4, Recruiting, 2022, 30 people, 9 Aug 2022, clinicaltrials.gov

NCT04985201

Phase 2, Status unknown, 2021, 40 people, 2 Aug 2021, clinicaltrials.gov

NCT04772287

Phase 3, Not yet recruiting, 2021, 341 people, 26 Feb 2021, clinicaltrials.gov

NCT04716751

Phase 2, Status unknown, 2021, 15 people, 20 Jan 2021, clinicaltrials.gov

NCT04698941

Phase 2, Status unknown, 2021, 40 people, 7 Jan 2021, clinicaltrials.gov

NCT04696939

Phase 2, Status unknown, 2021, 100 people, 6 Jan 2021, clinicaltrials.gov

NCT04542369

Phase 2, Status unknown, 2021, 15 people, 9 Sept 2020, clinicaltrials.gov